The CRC Blueprint

My scientific approach to my own cancer – shared with you.

Recruiting now

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

Phase 2 · 167 people · 4 sites in United Kingdom · Recruiting now

August 11, 2026
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Phase 2 · 147 people · 21 sites in United States · Recruiting now

August 11, 2026
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

Phase 1 · 146 people · 10 sites in 3 countries · Recruiting now

August 11, 2026
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

Phase 2 · 178 people · 1 site in China · Recruiting now

August 11, 2026
Contact Radiotherapy for Rectal Cancer

Not phased · randomised · 110 people · 2 sites in Sweden · Recruiting now

August 11, 2026
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Phase 2 · 265 people · 16 sites in 2 countries · Recruiting now

August 11, 2026
BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases

Phase 2 · 17 people · 1 site in United States · Recruiting now

August 11, 2026
A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)

Phase 1 · 180 people · 5 sites in United States · Recruiting now

August 11, 2026
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma

Phase 2 · 164 people · 3 sites in United States · Recruiting now

August 11, 2026
Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer

Phase 2 · 64 people · 4 sites in United States · Recruiting now

August 11, 2026